Enhanced Crenolanib-Based Therapies for FLT3 Mutated Proliferative Disorders
Legal Citation
Summary of the Inventive Concept
The present invention relates to novel improvements and enhancements of crenolanib-based therapies for treating FLT3 mutated proliferative disorders, providing more effective, efficient, and safe treatment options for patients.
Background and Problem Solved
The original patent, 'Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment,' has limitations in terms of dosing, efficacy, and patient monitoring. The new inventive concept addresses these limitations by introducing systems, methods, and compositions that enhance the treatment outcomes and patient experience.
Detailed Description of the Inventive Concept
The new inventive concept encompasses a system for treating FLT3 mutated proliferative disorders, comprising a crenolanib administration module and a monitoring module for tracking FLT3 tyrosine kinase activity. The system adjusts the crenolanib administration based on the FLT3 tyrosine kinase activity, ensuring optimal treatment outcomes. Additionally, the inventive concept includes methods for enhancing the efficacy of crenolanib, compositions for treating FLT3 mutated proliferative disorders, and systems for monitoring and treating these disorders. These improvements provide more targeted, efficient, and safe treatment options for patients.
Novelty and Inventive Step
The new claims introduce novel and non-obvious improvements to the original patent, including the integration of FLT3 tyrosine kinase activity monitoring, co-administration of second pharmaceutical agents, and the use of FLT3-binding antibodies. These advancements provide a significant inventive step over the prior art, enabling more effective and efficient treatment of FLT3 mutated proliferative disorders.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include varying the dose and administration schedule of crenolanib, using different types of FLT3 inhibitors or antibodies, or incorporating additional monitoring modules for tracking patient response. These variations ensure broad conceptual coverage and adaptability to different treatment scenarios.
Potential Commercial Applications and Market
The enhanced crenolanib-based therapies have significant commercial potential in the pharmaceutical industry, particularly in the treatment of FLT3 mutated proliferative disorders. The target market includes patients with relapsed or refractory FLT3 mutated cancers, as well as healthcare providers and researchers seeking more effective and efficient treatment options.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical oncology, specifically targeted therapies for hematological malignancies with a focus on FLT3 tyrosine kinase inhibitors and cancer treatment methodologies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmacology or oncology, expertise in targeted cancer therapies, understanding of tyrosine kinase inhibition mechanisms, and knowledge of clinical treatment optimization strategies
Obviousness Rationale
A person having ordinary skill in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core methodology for treating FLT3 mutated proliferative disorders. The disclosed improvements in monitoring, dosage adjustment, and combination therapies are logical progressions that would be apparent to a skilled practitioner seeking to optimize crenolanib's therapeutic efficacy. These variations demonstrate incremental advancements consistent with standard pharmaceutical research and development practices.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,546 |
|---|---|
| Title | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment |
| Assignee(s) | Arog Pharmaceuticals, Inc. |